Technology | Focused Ultrasound Therapy | June 19, 2018

EDAP Announces FDA Clearance for Focal One HIFU Prostate Ablation System

Device combines MRI, ultrasound and biopsy data to direct ablation procedures in real time

June 19, 2018 — EDAP TMS SA has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Focal One device for the ablation of prostate tissue.

The Focal One high intensity focused ultrasound (HIFU) device is the first medical apparatus designed specifically for focal treatment of the prostate, according to the company. Focal One fuses magnetic resonance (MR) and 3-D biopsy data with real-time ultrasound imaging. This allows urologists to view integrated, detailed 3-D images of the prostate on a large monitor and direct high intensity ultrasound waves to ablate the targeted area.

With Focal One, urology surgeons can establish precise contours around the diseased tissue and ablate an even smaller portion of the prostate. This lessens the damage to healthy tissue, and minimizes side effects of incontinence and impotence for patients. Using Focal One, surgeons can customize the HIFU procedure for each patient and each clinical condition.

"Focal One is a great step forward in using this new and important ultrasound technology for prostate tissue ablation," said Brian Miles, M.D., urologist, professor of urology, Houston Methodist Hospital - Weill Cornell Medical College.  "Focal One's ability to merge MRI images, ultrasound images and biopsy data in order to precisely outline and treat just the diseased tissue area of the prostate is truly remarkable."

For more information: www.edap-tms.com

Related Content

SpaceOAR Hydrogel Now Available in Japan
News | Patient Positioning Radiation Therapy | July 16, 2018
Augmenix K.K. announced that SpaceOAR hydrogel, a soft, implanted absorbable gel spacer is now available to all...
iSchemaView Brings RAPID Imaging Platform to Australia and New Zealand
News | Stroke | July 13, 2018
iSchemaView has signed Diagnostic Imaging Australia (DIA) to be the exclusive distributor for the RAPID cerebrovascular...
Siemens Healthineers Launches Acuson Sequoia Ultrasound
Technology | Ultrasound Imaging | July 12, 2018
July 12, 2018 — Siemens Healthineers recently announced the launch of its new ultrasound system, the Acuson Sequoia.
EchoNous Vein Receives FDA Approval to Improve First-Time Peripheral IV Catheter Insertion
Technology | Ultrasound Imaging | July 12, 2018
EchoNous has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the EchoNous Vein, an ultrasound-...
Hologic Announces Availability of Viera Portable Breast Ultrasound System
Technology | Ultrasound Women's Health | July 11, 2018
Hologic’s new Viera portable breast ultrasound system is now available for purchase in the United States and Europe....
Healcerion Receives FDA Approval for Sonon 300L Handheld Ultrasound Device
Technology | Ultrasound Imaging | July 09, 2018
South Korea-based Healcerion launched the Sonon 300L wireless handheld ultrasound device to the U.S. market following U...
High-Strength MRI May Release Mercury from Amalgam Dental Fillings
News | Magnetic Resonance Imaging (MRI) | July 05, 2018
Exposure to ultra-high-strength magnetic resonance imaging (MRI) may release toxic mercury from amalgam fillings in...
Neural Analytics Inc. Receives CE Mark for Robotic Ultrasound System
Technology | Ultrasound Imaging | July 03, 2018
Medical robotics company Neural Analytics Inc. announced that it received CE Mark for its NeuralBot System, a robotic...
Ensuring that the FMDS for MRI safety is mounted outside Zone IV provides maximum early warning.

Ensuring that the FMDS for MRI safety is mounted outside Zone IV provides maximum early warning. (Images courtesy of Metrasens)

Feature | Magnetic Resonance Imaging (MRI) | July 03, 2018 | By Tobias Gilk
Nearly every job in the country is subject to certain health and safety regulations. Construction workers must wear...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
Overlay Init